What does B-CLL stand for?

B-Cell Chronic Lymphocytic Leukemia

This definition appears very rarely and is found in the following Acronym Finder categories:

Science, medicine, engineering, etc.

Other Resources:

<< Previous	Abbreviation Database Surfer		Next >>
Bacnet Application Controller Bio-Sensitive Application Specific Integrated Circuits for Smart Sensors in Medical and Environmental Monitoring Breath-by-Breath (oxygen/carbon dioxide transfer) Basketball Bacnet Building Controller Balkan-Combined Air Operations Center Brookline Coalition Against Substance Abuse (est. 2003; Massachusetts) Bethune-Cookman College (Florida) Broadband-Code Division Multiple Access Bearer Channel		Broadband Customer Premises Equipment Type B Contact Support Equipment Group Buffered charcoal Yeast Extract Agar Becton, Dickinson & Co. Buss-Durkee Hostility Inventory (also seen as BDHI) Birthday Blind-Decorrelating Detector B-Cell Diffuse Large Cell Lymphoma Block-Differential Orthogonal Frequency Division Multiplexing Balanced Electro-Absorption Modulator

Samples in periodicals archive:

The drug is currently not approved for the treatment of multiple sclerosis but is indicated for treating B-cell chronic lymphocytic leukemia in patients who have been treated with alkylating agents and who have failed fludarabine therapy.

MS drug linked to one death in clinical trial

a unit of German-based Schering AG, and is currently FDA-approved to treat a type of leukemia, B-cell chronic lymphocytic leukemia B-CLL).

FDA warns MS patients not to use Campath

Background: There are some patients with B-cell chronic lymphocytic leukemia who exhibit an extraordinary natural resistance to this malignancy, which lasts for many years.

Absolute CD4 and CD8 counts and CD4-to-CD8 ratios in eight patients ...

Argos Therapeutics today announced that dosing has been initiated in a Phase 1/2 clinical trial to test the activity and safety of AGS-005 in B-cell chronic lymphocytic leukemia (CLL).

B-Cell Chronic Lymphocytic Leukemia Clinical Trial Initiated with ...

18, 2001 Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that the Comprehensive Cancer Center of the Wake Forest University School of Medicine in Winston-Salem, NC has initiated the first formal evaluation of ONTAK(R) (denileukin diftitox) in patients diagnosed with fludarabine-refractory, CD25-positive, B-cell chronic lymphocytic leukemia (CLL).

Ligand's ONTAK to be Evaluated in Treatment of Patients with Chronic ...